The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Beam Therapeutics Inc.

BOSTON--(BUSINESS WIRE)--Karuna Therapeutics, Inc. (NASDAQ: KRTX), a biopharmaceutical company driven to discover, develop, and deliver transformative medicines for people living with psychiatric ...

Karuna Therapeutics Submits New Drug Application to U.S. Food and Drug Administration for KarXT for the Treatment of Schizophrenia

WAYNE, Pa., Oct. 03, 2023 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno ...

Aclaris Therapeutics Completes Enrollment in Phase 2b Study of ATI-1777 for Mild to Severe Atopic Dermatitis (ATI-1777-AD-202)

Akero Therapeutics Inc.

Spanish biotech SpliceBio has signed a licensing agreement with Spark Therapeutics to utilise the latter’s proprietary protein splicing platform and develop a gene therapy for an undisclosed ...

Spark Therapeutics partners with SpliceBio for gene therapy

One of the tracks of SLAS EU 2023 is Shaping the Future of Therapeutics. How do you believe 3D Imaging Mass Cytometry is shaping the future of therapeutics? At the moment, I think 3D imaging mass ...

Shaping the Future of Therapeutics with 3D Imaging Mass Cytometry

Piper Sandler analyst Joseph Catanzaro maintained a Buy rating on Repare Therapeutics (RPTX – Research Report) today and set a price target of $25.00. The company’s shares closed last Friday ...

Piper Sandler Keeps Their Buy Rating on Repare Therapeutics (RPTX)

SkyGem Acquisition has launched a mandatory offer to buy the remaining shares of Allergy Therapeutics after increasing its shareholding past 30%, in a deal that values the company at 47.9 million ...

Allergy Therapeutics Gets GBP48 Million Takeover Offer From SkyGem

Knight Therapeutics Inc. disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information or future events, except as required by ...

Knight Therapeutics Announces Regulatory Submission of Pemigatinib in Brazil

Glenmark Pharmaceuticals Ltd on Thursday said its wholly-owned arm Ichnos Sciences has signed an exclusive worldwide licensing agreement with Astria Therapeutics for its OX40 antagonist monoclonal ...

Glenmark arm inks licensing pact with Astria Therapeutics

You’re reading the web edition of STAT’s Health Tech newsletter, our guide to how technology is transforming the life sciences. Sign up to get it delivered in your inbox every Tuesday and ...

Better Therapeutics data on apps’ benefit with GLP-1s, Orexo hits a snag

The effectiveness of mRNA vaccines has sparked significant interest and conversation around novel therapeutics for a range of diseases. The recent award of the 2023 Nobel Prize in Physiology or ...

Delivering on the Promise of Personalized mRNA Therapeutics

Oxford, United Kingdom – 11 October 2023 – OMass Therapeutics (‘OMass’ or ‘the Company’), a biotechnology company identifying medicines against highly validated target ecosystems, is pleased to confirm that it will be presenting at and ...

OMass Therapeutics Announces its Attendance at Upcoming Conferences and Events

Bicycle Therapeutics has strong collaborations and a robust cash position but faces escalating R&D costs and high short interest. Preclinical data for Pb-BCY20603 is promising, yet transitioning ...

Bicycle Therapeutics: Pedaling Through Uncertainty

Shares of Akero Therapeutics (NASDAQ: AKRO) were crashing 66.5% lower as of 11:09 a.m. ET on Tuesday. The steep decline came after the company announced interim results from a phase 2b clinical ...

Why Akero Therapeutics Stock Is Crashing Today

Mirati Therapeutics (NASDAQ:MRTX) could see another potential bidder as the deal with Bristol-Myers Squibb (NYSE:BMY) is lower than expected, according to a Leerink analyst. There's unlikely to be ...

Mirati Therapeutics could see another bidder emerge, Leerink says

Bloomberg / Contributor / Getty Images Bristol-Myers Squibb agreed to pay up to $5.8 billion for Mirati Therapeutics to boost its portfolio of cancer-fighting treatments. The initial payout to ...

Bristol-Myers Squibb Buys Mirati Therapeutics to Boost Cancer Drug Portfolio

(Bloomberg) -- Bristol-Myers Squibb Co. agreed to buy drugmaker Mirati Therapeutics Inc. for $4.8 billion to expand its aging portfolio of cancer drugs. Mirati shareholders will receive $58 a ...

Bristol Myers to Buy Mirati Therapeutics for $4.8 Billion

Israel reports killing top Hamas commanders, 'eliminating' other key terror operatives in Gaza airstrikes Georgia's top court clears move to remove president About ...

Bristol-Myers Squibb to acquire Mirati Therapeutics for $4.8B

Oct 6 (Reuters) - Amgen (AMGN.O) said on Friday it had completed the $27.8 billion acquisition of Horizon Therapeutics (HZNP.O) after it received the go-ahead from the U.S. Federal Trade ...

Amgen completes $27.8 billion Horizon Therapeutics deal

Acquisition includes company’s inflammatory disease medicines. Amgen revealed in a company press release that it has officially finished its purchase of Horizon Therapeutics for an approximate value of $27.8 billion. According to the company, the ...

Amgen Completes Purchase of Horizon Therapeutics

(RTTNews) - Amgen Inc. (AMGN), a biopharmaceutical company, announced on Friday that it has completed the acquisition of Horizon Therapeutics plc (HZNPN.MX). The company bought the outstanding ...

Amgen Concludes Horizon Therapeutics Acquisition

Orchard Therapeutics — Shares nearly doubled after Japanese pharmaceutical company Kyowa Kirin announced plans to acquire the biotechnology firm, which specializes in gene therapy, for $478 million.

Stocks making the biggest moves midday: Rivian, Orchard Therapeutics, Lamb Weston and more

Orchard Therapeutics, a small-cap gene therapy company, landed a premium-rich buyout offer from Kyowa Kirin today. With biotech valuations under pressure from high-interest rates, this deal may be ...

Why Orchard Therapeutics Stock Is Soaring Today

Atriva Therapeutics

Atriva Therapeutics GmbH manufactures and distributes pharmaceutical products. The Company offers inhibitors against seasonal and pandemic influenza. Atriva Therapeutics markets its products in Germany.

ATRIVA THERAPEUTICS

atriva-therapeutics.com

10 emps

Since 2015

Atriva Therapeutics's latest news & mentions

Beam Therapeutics Inc.

Karuna Therapeutics Submits New Drug Application to U.S. Food and Drug Administration for KarXT for the Treatment of Schizophrenia

Aclaris Therapeutics Completes Enrollment in Phase 2b Study of ATI-1777 for Mild to Severe Atopic Dermatitis (ATI-1777-AD-202)

Akero Therapeutics Inc.

Spark Therapeutics partners with SpliceBio for gene therapy

Shaping the Future of Therapeutics with 3D Imaging Mass Cytometry

Piper Sandler Keeps Their Buy Rating on Repare Therapeutics (RPTX)

Allergy Therapeutics Gets GBP48 Million Takeover Offer From SkyGem

Knight Therapeutics Announces Regulatory Submission of Pemigatinib in Brazil

Glenmark arm inks licensing pact with Astria Therapeutics

Better Therapeutics data on apps’ benefit with GLP-1s, Orexo hits a snag

Delivering on the Promise of Personalized mRNA Therapeutics

OMass Therapeutics Announces its Attendance at Upcoming Conferences and Events

Bicycle Therapeutics: Pedaling Through Uncertainty

Why Akero Therapeutics Stock Is Crashing Today

Mirati Therapeutics could see another bidder emerge, Leerink says

Bristol-Myers Squibb Buys Mirati Therapeutics to Boost Cancer Drug Portfolio

Bristol Myers to Buy Mirati Therapeutics for $4.8 Billion

Bristol-Myers Squibb to acquire Mirati Therapeutics for $4.8B

Amgen completes $27.8 billion Horizon Therapeutics deal

Amgen Completes Purchase of Horizon Therapeutics

Amgen Concludes Horizon Therapeutics Acquisition

Stocks making the biggest moves midday: Rivian, Orchard Therapeutics, Lamb Weston and more

Why Orchard Therapeutics Stock Is Soaring Today

Representing this company? Click here to claim and customize this page!

Reviews About Atriva Therapeutics

Atriva Therapeutics WIKI

Apply to get your Tech Company News Page live on HackerNoon.com today!

Light-Mode

Classic

Newspaper

Minty

Dark-Mode

Neon Noir

Minty

HN StartUps